We, therefore, conducted similar analysis to determine whether the elevated TORC1 activity in lymphoblasts might perform better as a biomarker of ME/CFS than the lymphocyte death rates or the lymphoblast respiratory dysfunction. This evidence concerns the gene CRTC1 and myalgic encephalomeyelitis/chronic fatigue syndrome.